



## Prior Authorization Checklist for TriClip™ Transcatheter Edge-To-Edge Repair

This checklist summarizes the information used to process prior authorization requests for the Tricuspid Transcatheter Edge-To-Edge Repair (Tricuspid TEER) procedures using the TriClip™ G4 system. The Tricuspid TEER procedure is also known as transcatheter tricuspid valve repair (TTVr). ICD-10-CM diagnosis<sup>1</sup> codes that may apply to Tricuspid TEER procedures include:

- **I36.1:** Nonrheumatic tricuspid (valve) insufficiency
- **I36.8:** Other nonrheumatic tricuspid valve disorders
- **I36.9:** Nonrheumatic tricuspid valve disorder, unspecified

This list of codes is not all-inclusive. For non-Medicare payers, consult local medical coverage policies for guidance. **Prior authorization and/or appeals must be obtained for Medicare Advantage and third-party commercial insurance plans.**

**Please do not include this form in your submission to the payer.**

CPT <sup>†</sup> CODES	DESCRIPTION	INCLUDED
<b>0569T *</b>	Transcatheter tricuspid valve repair percutaneous approach	<input type="checkbox"/>
<b>+ 0570T</b>	Transcatheter tricuspid valve repair percutaneous approach. Additional prosthesis during same session (List separately in addition to code for primary procedure). (Use +0570T in conjunction with 0569T)	<input type="checkbox"/>

\* For the TEER procedure, physician services (33418), echocardiography, and anesthesia are only payable when billed by separate practitioners.<sup>2</sup>

+ Indicates add-on code. List add-on code separately in addition to code for primary procedure.

It is the sole responsibility of the prescribing healthcare provider to diagnose and treat the patient. Nothing in this document is intended to interfere with the independent clinical judgment of the prescribing healthcare provider. This information is subject to change. Please check your patient's benefit administrator's prior authorization requirements before submitting a prior authorization request.

The following clinical information may be required when submitting a prior authorization request for the aforementioned CPT<sup>‡</sup> codes. **While all the criteria below may not be required for each case, it's best practice to consider documenting the information categories below in a prior authorization request form:**

INFORMATION CATEGORIES	CONSIDERATIONS	INCLUDED
<b>TR Diagnosis and Severity Determination</b>	<ul style="list-style-type: none"> <li>The multidisciplinary heart team should confirm the TR diagnosis and the severity/ TR grade</li> <li>All echocardiography data must be presented to support the diagnosis</li> </ul>	<input type="checkbox"/>
<b>Clinical Signs and Symptoms</b>	<ul style="list-style-type: none"> <li>Document TR disease clinical signs (e.g., effective regurgitant orifice area (EROA), regurgitant volume, regurgitant jet area, vena contracta width, RVEDD, tricuspid annular diameter, and right atrial volume)</li> <li>Document clinical symptoms (e.g., edema, ascites, painful hepatosplenomegaly, shortness of breath, NYHA class, 6-min walking score, and overall symptoms' impact on the quality of life)</li> </ul>	<input type="checkbox"/>
<b>Patient's Treatment History</b>	<ul style="list-style-type: none"> <li>Document the currently ongoing treatment's success or failure in controlling TR symptoms and progress (for example use of diuretics, heart failure management, etc.)</li> <li>Document former treatment modalities' success or failure in controlling TR symptoms and progress</li> <li>The multidisciplinary heart team should indicate whether the patient is at intermediate or greater risk for tricuspid surgery and Tricuspid TEER is clinically appropriate</li> </ul>	<input type="checkbox"/>

### ADDITIONAL PRIOR AUTHORIZATION AND APPEAL SUPPORT

Should your office need any additional reimbursement support materials or have any questions about the prior authorization or appeal process for your patients, please contact the Abbott support teams:

- For timely support with **prior authorizations, denials, and pre-procedural appeals**, contact the **Patient Therapy Access (PTA) team**. PTA specialists support Medicare Advantage and private payers' prior authorization and appeal processes on behalf of your patients. PTA specialists are available to your patients regardless of provider. For further information about the PTA service, please contact the team via:
  - Email: [PTA\\_Cardiac@abbott.com](mailto:PTA_Cardiac@abbott.com)
  - Phone: **(877) 706 - 7246**
- For Tricuspid TEER-specific coverage, coding, or payment questions, contact the **Health Economics and Reimbursement Field Team**:
  - Email: [AbbottEconomics@abbott.com](mailto:AbbottEconomics@abbott.com)

**Rx Only****Important Safety Information****TRICLIP™ G4 SYSTEM****INDICATIONS**

The TriClip™ G4 System is indicated for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy, who are at intermediate or greater risk for surgery and in whom transcatheter edge-to-edge valve repair is clinically appropriate and is expected to reduce tricuspid regurgitation severity to moderate or less, as determined by a multidisciplinary heart team.

**CONTRAINDICATIONS**

The TriClip G4 System is contraindicated in patients with the following conditions: Intolerance, including allergy or untreatable hypersensitivity, to procedural anticoagulation; Untreatable hypersensitivity to Implant components (nickel-titanium alloy, cobalt-chromium alloy); Active endocarditis or other active infection of the tricuspid valve.

**POTENTIAL ADVERSE EVENTS**

The following events have been identified as possible complications of the TriClip G4 Procedure. Allergic reactions or hypersensitivity to latex, contrast agent, anaesthesia, device materials and drug reactions to anticoagulation, or antiplatelet drugs; Additional treatment/surgery from device-related complications; Bleeding; Blood disorders (including coagulopathy, hemolysis, and heparin induced thrombocytopenia (HIT)); Cardiac arrhythmias (including conduction disorders, atrial arrhythmias, ventricular arrhythmias); Cardiac ischemic conditions (including myocardial infarction, myocardial ischemia, unstable angina, and stable angina); Cardiac perforation; Cardiac tamponade; Chest pain; Death; Dyspnea; Edema; Embolization (device or components of the device); Endocarditis; Fever or hyperthermia; Fluoroscopy and transesophageal echocardiogram (TEE) related complications: Skin injury or tissue changes due to exposure to ionizing radiation, Esophageal irritation, Esophageal perforation, Gastrointestinal bleeding; Hypotension/hypertension; Infection including: Septicemia; Nausea or vomiting; Pain; Pericardial effusion; Stroke/cerebrovascular accident (CVA) and transient ischemic attack (TIA); System organ failure: Cardio-respiratory arrest, Worsening heart failure, Pulmonary congestion, Respiratory dysfunction or failure or atelectasis, Renal insufficiency or failure, Shock (including cardiogenic and anaphylactic); Thrombosis; Tricuspid valve complications, which may complicate or prevent later surgical repair, including: Chordal entanglement/rupture, Single leaflet device attachment (SLDA), Dislodgement of previously implanted devices, Tissue damage, Tricuspid valve stenosis, Worsening, persistent or residual regurgitation; Vascular access complications which may require additional intervention, including: Wound dehiscence, Bleeding of the access site, Arteriovenous fistula pseudoaneurysm, aneurysm, dissection, perforation (rupture), vascular occlusion, Embolism (air, thrombus), Peripheral nerve injury; Venous thrombosis (including deep vein thrombosis) and thromboembolism (including pulmonary embolism).

**Disclaimer**

This material and the information contained herein is for general information purposes only and is not intended, and does not constitute, legal, reimbursement, business, clinical, or other advice. Furthermore, it is not intended to and does not constitute a representation or guarantee of reimbursement, payment, or charge, or that reimbursement or other payment will be received. It is not intended to increase or maximize payment by any payer. Abbott makes no express or implied warranty or guarantee that the list of codes and narratives in this document is complete or error-free. Similarly, nothing in this document should be viewed as instructions for selecting any particular code, and Abbott does not advocate or warrant the appropriateness of the use of any particular code. The ultimate responsibility for coding and obtaining payment/reimbursement remains with the customer. This includes the responsibility for accuracy and veracity of all coding and claims submitted to third-party payers. In addition, the customer should note that laws, regulations, and coverage policies are complex and are updated frequently and is subject to change without notice. The customer should check with its local carriers or intermediaries often and should consult with legal counsel or a financial, coding, or reimbursement specialist for any questions related to coding, billing, reimbursement, or any related issues. This material reproduces information for reference purposes only. It is not provided or authorized for marketing use.

**References:**

1. CMS\_2024\_ICD-10-CM <https://www.cms.gov/medicare/icd-10/2023-icd-10-cm>
2. National Correct Coding Initiative Edits. <https://www.cms.gov/Medicare/Coding/NCCI-Coding-Edits>

Information contained herein for DISTRIBUTION in the U.S. ONLY.

**Abbott**

3200 Lakeside Dr., Santa Clara, CA 95054 USA Tel: 1.800.227.9902  
www.cardiovascular.abbott

™ Indicates a trademark of the Abbott group of companies

‡ Indicates third party trademark, which is the property of its respective owner.

©2024 Abbott. All rights reserved. MAT-2311803 v1.0 | Item approved for U.S. use only.

